Hyliion finally has something better than a concept slide. Q1 2026 revenue came in at $2.8 million, up from $0.5 million a year ago, and management just cleared all non-recurring UL certification testing across the battery system, linear electric motor, and complete power module. That matters because HYLN has spent years as a story stock. …
If you want the short version, a safe withdrawal rate in 2026 is probably closer to 3.5% to 3.9% for most early retirees, not the lazy internet version of 4% that gets repeated like gospel. That does not mean the 4% rule is fake. It means your retirement timeline, healthcare costs, and willingness to cut …
If you want the short version, the best dividend stocks for 2026 are Realty Income (O), AbbVie (ABBV), and Chevron (CVX). They are not the highest-yield names on the screen, but that is the point. I would rather own a 3% to 6% yielder with real revenue, real balance-sheet support, and a visible 2026 catalyst …
Yext (NYSE: YEXT) looks dull until you get past the stock chart. The business did $446.6 million in fiscal 2026 revenue, produced $107.3 million in adjusted EBITDA, stayed profitable, and now has an AI-search product management thinks can matter. That is the bull case. The bear case is easier: this is still a slow-growth software …
ARDX Stock Analysis: Growth Is Real, So Is the Spend Ardelyx just posted the kind of quarter biotech investors usually beg for: real product revenue, real growth, and enough cash to avoid the usual panic about the next dilutive raise. The catch is that ARDX is no longer a cheap story. At roughly a $1.7 …
Agenus is a real biotech catalyst trade, not a hidden value stock. At roughly a $144 million market cap, with Phase 2 melanoma data due at ASCO on May 31 and a first-quarter corporate update scheduled for May 11, the setup is obvious: if the botensilimab story keeps getting cleaner, the stock can move fast. …
PROK stock is one of those setups where the upside story is obvious and the holding-period pain is obvious too. ProKidney has a sub-$300 million market cap, roughly $271.7 million in cash from its last reported quarter, a Phase 3 kidney-disease program with FDA alignment on an accelerated path, and a stock that still trades …
The Tariff Problem Is Real. Here’s How to Play It. Every small-cap investor is asking the same question in May 2026: which companies actually survive the tariff cycle without getting clipped? The answer isn’t complicated. You find companies where revenue stays inside US borders — no Chinese supply chain, no export dependency, no “we’re monitoring …
Berkshire Hathaway just reported a record $397.4 billion in cash. The S&P 500 sits at 5,521, trading at a forward P/E of 20.9 — 28% above its 25-year average. And Warren Buffett called the current market a “casino.” We’re entering the weakest six-month stretch of the four-year presidential cycle. Here’s what the data says, what …
PBYI Stock Analysis: Puma Biotechnology Looks Cheap, but the Pipeline Still Has to Matter This PBYI stock analysis starts with the obvious part: Puma Biotechnology looks cheap on a screen. The company is profitable, it trades around 12x trailing earnings, it finished 2025 with $97.5 million in cash and marketable securities, and management is guiding …